Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Terbinafine Tablets Generic Name & Formulations
Legal Class
Rx
General Description
Terbinafine HCl 250mg.
Pharmacological Class
Allylamine antifungal.
How Supplied
Contact supplier
Manufacturer
Terbinafine Tablets Indications
Indications
Onychomycosis of the toenail or fingernail due to tinea unguium.
Terbinafine Tablets Dosage and Administration
Adult
250mg once daily for 6 weeks (fingernail) or 12 weeks (toenail).
Children
Not established.
Terbinafine Tablets Contraindications
Contraindications
Chronic or active liver disease.
Terbinafine Tablets Boxed Warnings
Not Applicable
Terbinafine Tablets Warnings/Precautions
Warnings/Precautions
Onychomycosis: confirm diagnosis with nail specimen. Perform LFTs prior to and periodically during treatment. Discontinue if hepatic injury, progressive skin rash (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS), taste/smell disturbances, severe neutropenia (neutrophils ≤1000 cells/mm3), thrombotic microangiopathy occur, or if lupus erythematosus is suspected. Monitor CBCs if immunodeficient. Renal impairment (CrCl <50mL/min). Pregnancy (Cat.B), nursing mothers: not recommended.
Terbinafine Tablets Pharmacokinetics
See Literature
Terbinafine Tablets Interactions
Interactions
Antagonized by rifampin. May be potentiated by cimetidine or CYP2C9 and CYP3A4 inhibitors (eg, fluconazole, ketoconazole, amiodarone). May potentiate caffeine or drugs metabolized by CYP2D6 (eg, tricyclic antidepressants, SSRIs, beta-blockers). May antagonize cyclosporine.
Terbinafine Tablets Adverse Reactions
Adverse Reactions
Headache, diarrhea, rash, dyspepsia, liver enzyme abnormalities, pruritus, taste disturbances, nausea, abdominal pain, flatulence, urticaria; hepatotoxicity, depressive symptoms, smell disturbances.
Terbinafine Tablets Clinical Trials
See Literature
Terbinafine Tablets Note
Notes
Formerly known under the brand name Lamisil.
Terbinafine Tablets Patient Counseling
See Literature
